Host-Directed Therapies for Tuberculosis.

Published

Journal Article (Review)

Host-directed therapies are a relatively new and promising approach to treatment of tuberculosis. Modulation of specific host immune pathways, including those that impact inflammation and immunopathology, can limit mycobacterial infection and pathology, both in cell culture and in animal models. This review explores a range of host pathways and drugs, some already approved for clinical use that have the potential to provide new adjunctive therapies for tuberculosis. Drugs targeting host processes may largely avoid the development of bacterial antibiotic resistance, a major public health concern for tuberculosis. However, these drugs may also have generally increased risk for side effects on the host. Understanding the specific mechanisms by which these drugs act and the relationship of these mechanisms to Mycobacterium tuberculosis pathogenesis will be critical in selecting appropriate host-directed therapy. Overall, these host-directed compounds provide a novel strategy for antituberculosis therapy.

Full Text

Duke Authors

Cited Authors

  • Tobin, DM

Published Date

  • May 18, 2015

Published In

Volume / Issue

  • 5 / 10

PubMed ID

  • 25986592

Pubmed Central ID

  • 25986592

Electronic International Standard Serial Number (EISSN)

  • 2157-1422

International Standard Serial Number (ISSN)

  • 2157-1422

Digital Object Identifier (DOI)

  • 10.1101/cshperspect.a021196

Language

  • eng